Precise immunological classification guidance for early initiation of antiviral therapy in patients with chronic HBV infection
10.3760/cma.j.cn501113-20230203-00032
- VernacularTitle:精准免疫分期指导慢性HBV感染者尽早启动抗病毒治疗
- Author:
Suxian ZHAO
1
;
Chudi CHANG
;
Yuemin NAN
Author Information
1. 河北医科大学第三医院中西医结合肝病科 河北省慢性肝病肝纤维化研究重点实验室，石家庄 050051
- Keywords:
Hepatitis B virus;
Infection;
Immunology;
Phases;
Antiviral therapy
- From:
Chinese Journal of Hepatology
2023;31(3):228-232
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B virus (HBV) infection is a major problem affecting global public health. Appropriate antiviral therapy use can prevent or delay the occurrence of liver cirrhosis and liver cancer. Precise immunological classification can be helpful to formulate personalized therapy and management plans for HBV-infected patients. Antiviral therapy should be started early in those who meet antiviral indications, and nucleos(t)ide analogue therapeutic regimens alone or in combination with pegylated interferon alpha should be optimized according to antiviral therapy response, in order to maximize the realization of virological and serological response, improve clinical cure rate, and enhance long-term prognosis.
